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In July 2005, the World Health Organization added methadone and buprenorphine 
to its Model List of Essential Medicines.1 Methadone and buprenorphine are two 
of the best studied and most effective treatments for opiate addiction. Regular use 
of these medications, sometimes referred to as medication-assisted or substitution 
treatment, has been associated with decreased injecting drug use,2 decreased crimi-
nal activity,3 increased retention in treatment for chemical dependence,4 increased 
adherence to HIV medication,5 improved family relations,6 and successful return to 
employment.7
Available in developed countries
In developed countries, medication-assisted treatment is a 
standard option for people who are dependent on opiates, 
with more than 800,000 patients prescribed buprenorphine 
or methadone as of 2005: 237,000 patients in the United 
States,8 an estimated 530,000 patients in Western Europe,9 
39,000 patients in Australia,10 and 4,000 in New Zealand.11 
Many European countries facing growing HIV epidemics 
among injecting drug users (IDUs) have rapidly scaled up 
treatment. Germany, for example, legalized methadone 
treatment in 1987; by 2005, the country had about 60,000 
patients on treatment. In France, 85,000 people had received 
buprenorphine treatment as of November 2006, with 
medication prescribed by general practitioners and available 
in pharmacies.12
Inaccessible in developing countries
In developing and transitional countries with injection-
driven HIV epidemics, methadone and buprenorphine 
remain largely unavailable or inaccessible. With injection 
drug use accounting for ever greater numbers of HIV 
infections—UNAIDS estimates that nearly one-third 
of new infections outside Africa are among IDUs—the 
implications of failure to provide treatment are striking. 
As of 2007, less than 2 percent of IDUs in countries with 
injection-driven HIV epidemics were accessing metha-
done or buprenorphine treatment in government clinics.13 
The greatest share of patients were in China, where 320 
clinics provided services to 36,000 people as of March 
2007,14 and in Iran, where about 60,000 people received 
methadone and between 5,000-8,000 received buprenor-
phine through government clinics or private physicians.15 
In Eastern Europe and Central Asia, access to metha-
done or buprenorphine is similarly low; less than 2 per-
cent of estimated IDUs receive treatment. Some progress 
is being made, however. The Global Fund to Fight AIDS, 
Tuberculosis and Malaria has supported methadone or 
buprenorphine treatment scale-up or pilot projects in 
countries with injection-driven epidemics, including 
Azerbaijan, Belarus, China, Estonia, Georgia, Indonesia, 
Kyrgyzstan, Moldova, Ukraine, and Uzbekistan. China, 
Iran, Malaysia, and Ukraine all plan to increase the scale 
of methadone or buprenorphine programs sharply in the 
coming years, while other countries—including Vietnam, 
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Kazakhstan, and Tajikistan—have received grants from 
international donors and pledged to start pilot projects. 
Barriers to  
Medication-assisted 
treatMent 
Even in countries where methadone and buprenorphine 
are technically available, access to treatment for patients 
in need is limited by many factors, including the high 
costs and low supply of medication, restrictive entry 
criteria for treatment programs, and lack of government 
commitment to scale up pilot projects.  
High costs and Low supply
Costs of medication 
Prices for buprenorphine and methadone vary widely 
around the world, and in some cases differ within coun-
tries depending on supplier, import fees, and local health 
care regulations and practice. In China, for example, 
where methadone is locally manufactured, the price 
of an average dose of the medication to patients varies 
between 5-10 Yuan a day (US$0.66-1.30).16 Iran makes 
methadone available for approximately US$0.25 for 100 
milligrams, and generic buprenorphine for US$1.30 for 
8 milligrams. In other countries with injection-driven 
epidemics, governments pay higher prices for medica-
tion by agreement with pharmaceutical manufacturers. 
In Indonesia, for example, an average dose of methadone 
costs between US$0.54 and US$1.62, depending on loca-
tion.17 Governments have occasionally exercised their abil-
ity to renegotiate the pricing structure; in Malaysia, the 
price of methadone started at US$10 for 40 milligrams, 
but government negotiations with suppliers brought the 
price down to approximately US$0.80 per 40 milligrams 
in 2007.18
Methadone is generally cheaper than buprenor-
phine. In Ukraine, for example, methadone had not 
been dispensed as of December 2007, but  govern-
ment plans called for treatment with the medication at 
a price of approximately US$9 per patient per month. 
Buprenorphine has been available since 2005 and as of 
late 2007 was prescribed to approximately 500 patients, 
but at about 10 times the cost expected for methadone.19 
Health care providers sometimes find other ways to 
pass costs on to patients. In Azerbaijan, for example, 
informal reports indicate that people are being asked 
to pay costs as high as US$500 for treatment that was 
meant to be free. In Georgia, where only 225 patients had 
access to free treatment in 2007, the government is con-
sidering opening fee-for-service clinics where treatment 
would cost around 150 GEL (US$95) per month. At more 
than half the average monthly salary,20 these fees would 
be prohibitive. 
Irregular supply and treatment interruptions
Supply interruptions, or the threat of them, have resulted 
in discontinuation of treatment or sudden reductions in 
dosages. In Simferopol, Ukraine, in late April 2007, clients 
reportedly received their doses “only every other day” for 
about two weeks.21 In Azerbaijan, methadone treatment 
was discontinued in 2005 when clinics did not receive 
new supplies. In Kyrgyzstan, patients had their methadone 
doses sharply reduced or were urged to stop treatment in 
2005 due to delays in procurement and distribution.  
Difficulties with law enforcement  
and police harassment
The costs of receiving methadone or buprenorphine treat-
ment often include harassment from law enforcement. 
In Kyrgyzstan, police have stationed themselves outside 
methadone clinics, often arresting patients or threatening 
to plant drugs on them unless they pay bribes. In Odessa, 
Ukraine, buprenorphine patients report that police offi-
cers regularly extort money and threaten to plant drugs 
on them.22 Although the Malaysian government endorsed 
the establishment of methadone treatment programs in 
2005, laws and policies criminalizing drug users result 
in police raids and arrests at methadone programs.23 
Methadone patients undergoing treatment in community 
clinics have their names added to the government regis-
tries of drug users. In Indonesia, organizations report that 
police are not well informed about methadone treatment’s 
legality and do not know that they are forbidden to make 
arrests in the clinic area; as a result, some patients report 
that they have become targets for the police because they 
use other drugs in addition to methadone.24
entry requirements and restrictions
Waiting lists 
Injecting drug users are often discouraged from enter-
ing treatment programs because of long waiting lists. In 
Ukraine, 300 people are reportedly on waiting lists. In 
Poland, the number of people receiving treatment has not 
risen above 1,000, or 2.5 percent of estimated IDUs, since 
treatment began in 1992. Waiting lists in several cities in 
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Poland are over 500 names long—greater than the num-
ber of those on treatment. Waiting lists are also reported 
in Georgia, Indonesia, Kyrgyzstan, and Malaysia.
Limited number of clinics and 
lack of take-home doses
While the United States and Western European countries 
allow buprenorphine provision through pharmacies and 
“take home” methadone doses for stable patients, these are 
prohibited in most countries of Eastern Europe and Central 
Asia. In Ukraine, participants are generally required to 
visit an AIDS center or narcological dispensary every day 
to receive their dose of buprenorphine, and to go without 
on Sunday when centers are closed. In Simferopol, the 
AIDS center is the only facility offering buprenorphine in 
the entire region, which means some patients must travel 
several hours each day to the center from cities such as 
Yalta and Sevastopol.25 Patients are only allowed to receive 
medication at the clinic near their permanent residence, 
making travel effectively impossible.
Age requirements or history of multiple  
documented attempts at abstinence
In Ukraine, patients must be at least 18 years old, and have 
tried to quit illicit drug use at least three times through 
rehabilitation or detoxification programs.26 In Georgia, 
patients must be over the age of 25; be drug users for more 
than three years; be injecting for at least one year; and be 
able to document an unsuccessful treatment in a licensed 
institution.27 Some clinics also expel patients who test posi-
tive for drug use while enrolled in treatment, though this 
problem can frequently be addressed by adjusting the dose 
of medicine.28
While programs often allow fast-track entry for certain 
applicants—such as those with HIV, TB, cancer, diabetes, 
and mental disorders, or for pregnant women29—gen-
eral restrictions and the need to produce documentation 
frequently delay treatment for IDUs. 
Review by commission
Many countries, including Azerbaijan, Estonia, Georgia, 
Kyrgyzstan, Moldova, Poland, and Ukraine, require that 
patient cases be reviewed by commissions of as many as 
six members prior to entry into treatment. 
In Estonia, two psychiatrists must determine a 
person’s eligibility. Latvia and Lithuania require that 
commissions review patient eligibility; the Lithuanian 
commission is established by the chief doctor of the 
hospital. In Moldova, a commission of six people in the 
National Narcological Dispensary reviews an application. 
30 In Kyrgyzstan, the commission requires two years 
of drug use, several unsuccessful treatment attempts, 
opioid dependence complications, associated diseases, 
or pregnancy, as well as individual indications “deemed 
significant.” 31
In Georgia, a supervisory council of the Ministry of 
Health, Labor and Social Affairs reviews the cases of IDUs 
who do not meet the entry requirements for a methadone 
program. This council is composed of ministry represen-
tatives, several doctors from the Institute of Narcology, 
and one NGO representative; until recently, it also 
included a journalist. 32
Police control of entry
Changes to the protocol for entry into treatment are 
crucial to the scale-up of methadone and buprenorphine 
programs. In China, where expansion of methadone  
treatment has been widely praised, officials used to 
require that patients undergo up to a year of detention 
in compulsory detoxification facilities or forced labor 
camps prior to entry into a methadone program. Police 
often held the right to grant or deny admission. In July 
2006, China relaxed these requirements, though some 
clinics still impose them. Current guidelines indicate four 
conditions for entry into the program: patients must pass 
multiple times through drug treatment; must be over the 
age of 20; must be residents of the county, city, or district 
of the organization providing the treatment, or have a 
temporary residence permit; and must exhibit “civilized 
behavior.” The age limit is waived if the individual is  
HIV positive. 33
HIV positive status requirement
Some countries, including Ukraine and Uzbekistan, 
began medication-assisted treatment with restrictions 
limiting the number of those who are not HIV-infected 
who can receive treatment. Such a requirement effectively 
provides an incentive for HIV infection while denying 
treatment to those at risk.
Perpetual Pilot status  
Many methadone and buprenorphine treatment pro-
grams suffer “death by pilot,” when a program remains 
restricted in scale for years while government authorities 
evaluate its viability. Belarus began a pilot program  
for medication-assisted treatment in 2005 but the first 
patient did not receive treatment until 2007, despite 
the Global Fund’s willingness to pay for the costs of the 
medication. 34 In Poland, only about 1,000 people receive 
methadone treatment 16 years after methadone was intro-
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duced. In Kyrgyzstan, six years after methadone prescrip-
tion began, fewer than 200 people received treatment as 
of June 2007. Expansion to four additional clinics was 
achieved by year’s end.
Medication-assisted  
treatMent in Prison
The World Health Organization’s “Guidelines on HIV 
and AIDS in Prisons” recommend that prisoners on 
methadone maintenance prior to imprisonment should 
be able to continue this treatment while in prison. 35 
Unfortunately, in Eastern Europe and Asia, such treat-
ment remains largely unavailable to those incarcerated. 
Among developing and transitional countries where the 
largest share of HIV cases are among IDUs, Indonesia, 
Iran, and Moldova alone allowed patients to begin 
medication-assisted treatment in prison in 2007, while 
Poland offered short-term treatment only to patients 
who were on medication prior to incarceration. 36 As of 
mid-2007, 22 prisoners received methadone in Moldova 
but were required to taper their dosage after six months, 
which caused many of the prisoners to experience symp-
toms of withdrawal. 37 In Indonesia, methadone was 
available to 33 prisoners as of June 2006. 38 
Iran, where methadone treatment became available 
in prisons in 2003, is a notable exception. Methadone 
treatment in prison is part of a larger package of HIV 
prevention interventions provided through “triangu-
lar clinics.” The clinics focus on three priority areas: 
addressing IDUs through a harm reduction approach, 
treating sexually transmitted infections, and provid-
ing care and support for people living with HIV/AIDS. 
At the end of 2006, there were 55 triangular clinics in 
prisons, covering 33 percent of all prisoners, in addi-
tion to another 34 clinics in after-care centers outside 
of prisons. 39 As of January 2007 the triangular clinics 
provided methadone maintenance therapy to 55 percent 
of prisoners in need, with plans to cover 80–99 percent 
by 2008. 40 The clinics also provide needle and syringe 
exchange to prisoners and a few are providing antiretro-
viral therapy. 
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Experience has shown that methadone and buprenorphine are powerful tools for treating drug 
addiction, increasing access to HIV prevention and treatment, and improving the quality of life 
for individuals, families, and communities. Yet countless people continue to suffer because of 
delays in provision of these life-saving medications and a lack of large-scale, accessible treatment 
programs. For millions of opiate users in developing and transitional countries, increased com-
mitment to treatment availability will mean a new chance for improved health, function, and 
social participation. 
For more information and a footnoted version of this fact sheet, go to www.soros.org/harm-reduction
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